论文部分内容阅读
近年来失眠的药物治疗已成为全球研究人员面临的挑战。用于治疗失眠症的常规治疗药物是苯二氮n 类(BZD)(和非BZD(也称为z-药物)、三环抗抑郁药(TCA)多塞平以及褪黑素激动剂，但由于这些药物的重大副作用(如：宿醉反应、依赖性、耐受性、反弹失眠、肌肉酸痛、呼吸系统抑制、认知功能障碍和焦虑增加等)，使得他们解决睡眠问题的潜力受到限制。最近研究发现，食欲素神经肽是调节觉醒与睡眠之间的转变的一种因子，可帮助从过渡状态转为觉醒状态，作为治疗睡眠障碍的可能治疗靶标，与常规治疗相比具有较小副作用的优点。笔者对食欲素受体拮抗剂用于失眠症治疗的研究进展进行综述。n “,”In recent years, drug therapy for insomnia has become a challenge for researchers around the world.The conventional therapeutic agents for the treatment of insomnia are benzodiazepine(BZD) and non-BZD(also known as z-drug), tricyclic antidepressants(TCA) doxepin and melatonin agonists.But because of the significant side effects of these drugs(eg.hangover, dependency, tolerance, rebound, insomnia, respiratory depression, respiratory dysfunction, cognitive dysfunction and increased anxiety), their potential to solve sleep problems is limited.Recent studies have shown that orexin-like neuropeptides are a factor in regulating the transition between awakening and sleep, helping to switch from a transitional state to a conscious state as a possible therapeutic target for the treatment of sleep disorders, with less side effects than conventional therapy.This review focuses on the progress of orexin receptor antagonists as a sleep drug.